Adverum Biotechnologies Inc (ADVM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Adverum Biotechnologies Inc (ADVM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8235
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Adverum Biotechnologies Inc (Adverum), formerly Avalanche Biotechnologies Inc, is a clinical-stage gene therapy provider. The company’s product pipeline includes AVDM-053, ADVM-022 and AVA-311. Its products are used for treatment of antitrypsin deficiency, hereditary angioedema, wet age-related macular degeneration and juvenile X-linked retinoschisis a retinal disease caused by mutations. The company provides its ocular biofactory gene therapy platform to develop product candidates for rare diseases in the field of ophthalmology. It has collaborations with academic institutions and pharmaceutical companies, among others. It also offers research and development, pre clinical services and manufacturing services. Adverum is headquartered in Menlo Park, California, the US.

Adverum Biotechnologies Inc (ADVM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Avalanche Biotech Raises US$55 Million In Series B Venture Financing 12
Partnerships 14
Adverum Biotechnologies Extends Agreement with Editas Medicine 14
Synpromics Expanded its Research Agreement with Adverum Biotech 15
Regeneron Pharma Enters Into Co-Development Agreement With Avalanche Biotech For Gene Therapy Products 16
Licensing Agreements 17
Avalanche Biotech Enters into Licensing Agreement with University of Washington 17
GenSight Biologics Enters into Licensing Agreement with Avalanche Biotech 18
Equity Offering 20
Adverum Biotech Raises USD69 Million in Public Offering of Shares 20
Adverum Biotech to Raise up to USD50 Million in Public Offering of Shares 22
Avalanche Biotechnologies Raises USD140 Million in Public Offering of Shares 23
Avalanche Biotech Completes IPO for USD117 Million 25
Avalanche Biotech Raises USD10 Million in Private Placement of Shares 27
Acquisition 28
Avalanche Biotech Acquires Annapurna Therapeutics 28
Adverum Biotechnologies Inc – Key Competitors 30
Adverum Biotechnologies Inc – Key Employees 31
Adverum Biotechnologies Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Aug 08, 2018: Adverum Biotechnologies reports second quarter 2018 financial results and provides corporate update 33
May 09, 2018: Adverum Biotechnologies Reports First Quarter 2018 Financial Results and Provides Corporate Update 35
Mar 06, 2018: Adverum Biotechnologies Reports Fourth Quarter 2017 Financial Results and Provides Corporate Update 37
Nov 08, 2017: Adverum Biotechnologies Reports Third Quarter 2017 Financial Results and Provides Corporate Update 39
Aug 08, 2017: Adverum Biotechnologies Reports Second Quarter 2017 Financial Results and Provides Update 40
May 09, 2017: Adverum Biotechnologies Reports First Quarter 2017 Financial Results and Provides Update 41
Mar 06, 2017: Adverum Biotechnologies Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Update 42
Corporate Communications 44
Oct 17, 2018: Adverum Biotechnologies Announces Appointment of Leone Patterson as CEO and Member of the Board of Directors 44
May 03, 2018: Adverum Biotechnologies Announces Leadership Changes 45
Sep 07, 2017: Adverum Biotechnologies Appoints Eric G. Carter, M.D., Ph.D. to Board of Directors 46
Jun 20, 2017: Adverum Biotechnologies appoints senior vice president and chief medical officer 47
Apr 20, 2017: Adverum Biotechnologies Appoints Richard N. Spivey, Pharm.D., Ph.D. to Board of Directors 48
Mar 14, 2017: Adverum Biotechnologies Appoints Patrick Machado, J.D. to Board of Directors 49
Product News 50
Aug 01, 2018: Adverum Biotechnologies announces clinical progress across gene therapy Pipeline 50
Product Approvals 52
Jan 04, 2018: Adverum Biotechnologies Provides Update on its Hereditary Angioedema Drug Candidate ADVM-053 52
Other Significant Developments 53
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54

List of Tables
Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adverum Biotechnologies Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Avalanche Biotech Raises US$55 Million In Series B Venture Financing 12
Adverum Biotechnologies Extends Agreement with Editas Medicine 14
Synpromics Expanded its Research Agreement with Adverum Biotech 15
Regeneron Pharma Enters Into Co-Development Agreement With Avalanche Biotech For Gene Therapy Products 16
Avalanche Biotech Enters into Licensing Agreement with University of Washington 17
GenSight Biologics Enters into Licensing Agreement with Avalanche Biotech 18
Adverum Biotech Raises USD69 Million in Public Offering of Shares 20
Adverum Biotech to Raise up to USD50 Million in Public Offering of Shares 22
Avalanche Biotechnologies Raises USD140 Million in Public Offering of Shares 23
Avalanche Biotech Completes IPO for USD117 Million 25
Avalanche Biotech Raises USD10 Million in Private Placement of Shares 27
Avalanche Biotech Acquires Annapurna Therapeutics 28
Adverum Biotechnologies Inc, Key Competitors 30
Adverum Biotechnologies Inc, Key Employees 31
Adverum Biotechnologies Inc, Subsidiaries 32

List of Figures
Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adverum Biotechnologies Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Adverum Biotechnologies Inc (ADVM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Companhia Energetica de Minas Gerais – CEMIG:企業の戦略・SWOT・財務情報
    Companhia Energetica de Minas Gerais - CEMIG - Strategy, SWOT and Corporate Finance Report Summary Companhia Energetica de Minas Gerais - CEMIG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • Global Insurance Management Limited:企業の戦略・SWOT・財務分析
    Global Insurance Management Limited - Strategy, SWOT and Corporate Finance Report Summary Global Insurance Management Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Northern Ireland Electricity Networks Ltd:企業の戦略的SWOT分析
    Northern Ireland Electricity Networks Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Hill-Rom Holdings, Inc.:戦略・SWOT・企業財務分析
    Hill-Rom Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Hill-Rom Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Golden Star Resources Ltd:企業の戦略・SWOT・財務分析
    Golden Star Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Golden Star Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Shanghai RAAS Blood Products Co Ltd (002252):企業の財務・戦略的SWOT分析
    Shanghai RAAS Blood Products Co Ltd (002252) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Bioverativ Inc (BIVV):製薬・医療:M&Aディール及び事業提携情報
    Summary Bioverativ Inc (Bioverativ) is a biotechnology company that discovers, develops, and markets therapeutics for the treatment of hemophilia, and rare blood disorders. Its product portfolio includes Eloctate, which comprises recombinant antihemophilic factor engineered using Fc fusion technolog …
  • Ryder System, Inc.:企業の戦略・SWOT・財務情報
    Ryder System, Inc. - Strategy, SWOT and Corporate Finance Report Summary Ryder System, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Recurrent Energy LLC:電力:M&Aディール及び事業提携情報
    Summary Recurrent Energy LLC (Recurrent Energy), a subsidiary of Canadian Solar Inc. is a mainstream clean energy company that operates a portfolio of solar energy projects and generates electricity. The company develops and operates a portfolio of utility scale power projects. It has more than 4 GW …
  • Elekeiroz SA (ELEK3):企業の財務・戦略的SWOT分析
    Elekeiroz SA (ELEK3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Mercury NZ Limited:企業の戦略・SWOT・財務分析
    Mercury NZ Limited - Strategy, SWOT and Corporate Finance Report Summary Mercury NZ Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Verbundnetz Gas Aktiengesellschaft-石油・ガス分野:企業M&A・提携分析
    Summary Verbundnetz Gas Aktiengesellschaft (VNG), a subsidiary of EnBW Energie Baden-Wurttemberg AG, is a natural gas company that explores, produces, stores, trades and transports natural gas. The company has natural gas licenses on the Norwegian continental shelf and the Danish Central Graben regi …
  • Ornim Inc:医療機器:M&Aディール及び事業提携情報
    Summary Ornim Inc (Ornim) is a medical device company that specializes in clinical research, development and distribution of medical devices in the field of tissue and cerebral blood flow and perfusion, among others. The company’s c-FLOW is a continuous non-invasive monitor of deep tissue blood flow …
  • PlantForm Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary PlantForm Corp (PlantForm) is a biopharmaceutical company that develops and produces specialty antibody and protein drugs. The company’s pipeline products include biosimilar ranibizumab, trastuzumab, hD9 antibody for ricin exposure, recombinant butyrylcholinesterase, antibodies for HIV or AI …
  • Trustwave Holdings Inc:企業の戦略的SWOT分析
    Trustwave Holdings Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Tyson Foods Inc:企業の戦略・SWOT・財務情報
    Tyson Foods Inc - Strategy, SWOT and Corporate Finance Report Summary Tyson Foods Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • AEON Co Ltd (8267):企業の戦略的SWOT分析
    AEON Co Ltd (8267) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Idorsia Pharmaceutical Ltd (IDIA):製薬・医療:M&Aディール及び事業提携情報
    Summary Idorsia Pharmaceutical Ltd (Idorsia) is a manufacturer and developer of medicine that discovers, develops various therapies. The company provides pipeline portfolio such as investigational candidates targeted at the treatment of resistant hypertension, chronic insomnia, vasospasm, and system …
  • Daidalos Solutions BV:企業の製品パイプライン分析2018
    Summary Daidalos Solutions BV (Daidalos Solutions) is a medical device company. The company offers products such as sutureless biological heart valve prostheses, sutureless mechanical heart valve prostheses, sutureless heart valve repair rings, sutureless working channels and ports, sutureless closi …
  • J&P – Avax Sa:企業の戦略・SWOT・財務分析
    J&P - Avax Sa - Strategy, SWOT and Corporate Finance Report Summary J&P - Avax Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆